CAS Number106133-20-4
Synonymsamsulosin; Flomax; Tamsulosinum; 5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide; (R)-5-[2-[[2-(2-Ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide; Tamsulosine; Tamsulosina; 5-{(2R)-2-[(2-{[2-(ethyloxy)phenyl]oxy}ethyl)amino]propyl}-2-(methyloxy)benzenesulfonamide; Tamsulosin; Tamsolusin; MFCD00871531; Tamsulosina [INN-Spanish]; Tamsulosine [INN-French]; (R)-(-)-5-[2-(2-(2-ethoxyphenoxy)ethylamino)propyl]-2-methoxybenzenesulfonamide; 5-[(2R)-2-{[2-(2-Ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide; Tamsulosinum [INN-Latin]
Molecular FormulaC20H28O5N2S1
Molecular Weight408.52
Purity98%
Density1.2±0.1 g/cm3
Boiling Point595.5±60.0 °C at 760 mmHg
Melting Point226-228ºC
Appearancewhite crystal
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 106133-20-4 |
| Catalog No. | 2A-9012576 |
| Chinese Name | 坦索洛新 |
| Synonyms | amsulosin; Flomax; Tamsulosinum; 5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide; (R)-5-[2-[[2-(2-Ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide; Tamsulosine; Tamsulosina; 5-{(2R)-2-[(2-{[2-(ethyloxy)phenyl]oxy}ethyl)amino]propyl}-2-(methyloxy)benzenesulfonamide; Tamsulosin; Tamsolusin; MFCD00871531; Tamsulosina [INN-Spanish]; Tamsulosine [INN-French]; (R)-(-)-5-[2-(2-(2-ethoxyphenoxy)ethylamino)propyl]-2-methoxybenzenesulfonamide; 5-[(2R)-2-{[2-(2-Ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide; Tamsulosinum [INN-Latin] |
| Molecular Formula | C20H28O5N2S1 |
| Molecular Weight | 408.52 |
| Purity | 98 |
| Density | 1.2±0.1 g/cm3 |
| Boiling Point | 595.5±60.0 °C at 760 mmHg |
| Melting Point | 226-228ºC |
| Appearance | white crystal |
| Storage Condition | Room temperature, protected from light, dry and se |
| Application | Tamsulosin is an α1 receptor antagonist. |
| HTC | 2935009090 |
| MDL Number | MFCD00871531 |
| SMILES | CCOc1ccccc1OCCNC(C)Cc1ccc(OC)c(S(N)(=O)=O)c1 |
| InChI | InChI=1S/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-/m1/s1 |
| InChI Key | DRHKJLXJIQTDTD-OAHLLOKOSA-N |
| MSDS | msds/12576_1_106133_20_4.pdf |
| Use of | Tamsulosin is a selective α1 receptor antagonist.Target: α1 receptorTamsulosin is a selective α1 receptor antagonist that has preferential selectivity for the α1A receptor in the prostate versus the α1B receptor in the blood vessels. Tamsulosin-treated patients had a 0.30-fold lower risk of developing acute urinary retention compared with control patients. None of the International Continence Society male questionnaire domain scores showed significant changes between the groups [1]. tamsulosin can be recommended for treating men after catheterization for AUR, and can reduce the likelihood of the need for re-catheterization [2]. Properties Name tamsulosin Synonym More Synonyms Tamsulosin Biological Activity Description Tamsulosin is a selective α1 receptor antagonist.Target: α1 receptorTamsulosin is a selective α1 receptor antagonist that has preferential selectivity for the α1A receptor in the prostate versus the α1B receptor in the blood vessels. Tamsulosin-treated patients had a 0.30-fold lower risk of developing acute urinary retention compared with control patients. None of the International Continence Society male questionnaire domain scores showed significant changes between the groups [1]. tamsulosin can be recommended for treating men after catheterization for AUR, and can reduce the likelihood of the need for re-catheterization [2]. Related Catalog Research Areas >> Endocrinology Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor Research Areas >> Neurological Disease References [1]. Jeong, I.G., et al., Impact of tamsulosin on urinary retention following early catheter removal after robot-assisted laparoscopic radical prostatectomy: a prospective randomized controlled trial. Int J Urol, 2014. 21(2): p. 164-8. [2]. Lucas, M.G., T.P. Stephenson, and V. Nargund, Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int, 2005. 95(3): p. 354-7. Chemical & Physical Properties Molecular Formula C20H28N2O5S Exact Mass 408.171906 PSA 108.26000 Index of Refraction 1.553 InChIKey DRHKJLXJIQTDTD-OAHLLOKOSA-N Safety Information HS Code 2935009090 Synthetic Route 5-(2-((2-(2-eth... 852619-17-1 Tamsulosin hydr... 106463-17-6 Tamsulosin 106133-20-4 Literature: EP2172443 A1, ; Page/Page column 12 ; (R)-2-(2-ethoxy... 133261-17-3 Tamsulosin 106133-20-4 N,N-Dimethylfor... Tamsulosin 106133-20-4 Precursor & DownStream Precursor 4 CAS#:852619-17-1 5-(2-((2-(2-eth... CAS#:68-12-2 N,N-Dimethylfor... CAS#:106133-20-4 Tamsulosin CAS#:131029-01-1 1-(4-methoxyphe... DownStream 1 CAS#:106133-20-4 Tamsulosin |
| Tax Rebate | 9.0% |
| Supervision | None MFN tariff: 6.5% Ordinary tariff: 35.0% |
| Transport Info | Product name: Summary 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0% |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Stavudine | 3056-17-5 | 2A-9012507 |
| Sulfasalazine | 599-79-1 | 2A-9012526 |
| Sulindac sulfide | 32004-67-4 | 2A-9012534 |
| Tacrolimus | 104987-11-3 | 2A-9012563 |
| Tamoxifen | 10540-29-1 | 2A-9012574 |
| Tamsulosin hydrochloride | 106463-17-6 | 2A-9012577 |
| Tecloftalam metabolite | 26491-30-5 | 2A-9012603 |
| Telmisartan | 144701-48-4 | 2A-9012611 |
| Tenofovir | 147127-20-6 | 2A-9012625 |
| Tenofovir disoproxil | 202138-50-9 | 2A-9012626 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS